Stockreport

Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF per share, to help fund development and a potential commercial launch of its lead candidate IMVT-1402 for Graves' disease and other autoimmune conditions. A striking e [Read more]